{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:38:27Z","timestamp":1791308307663,"version":"4.3.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003443","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Ministerstwo Edukacji i Nauki","doi-asserted-by":"publisher","award":["075-15-2022-1103"],"award-info":[{"award-number":["075-15-2022-1103"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala Universitet","doi-asserted-by":"publisher","award":["UFV-PA 2022\/3323"],"award-info":[{"award-number":["UFV-PA 2022\/3323"]}],"id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.nucmedbio.2023.108384","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T02:38:06Z","timestamp":1693535886000},"page":"108384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3"],"prefix":"10.1016","volume":"124-125","author":[{"given":"Maryam","family":"Oroujeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina A.","family":"Bezverkhniaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenii V.","family":"Plotnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Klint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ryer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Karlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Orlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik Y.","family":"Frejd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Tolmachev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2023.108384_bb0005","first-page":"2021","article-title":"B7-H3\/CD276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101580","article-title":"Hopes on immunotherapy targeting B7-H3 in neuroblastoma","volume":"27","author":"Pulido","year":"2023","journal-title":"Transl Oncol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0015","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1038\/jid.2013.114","article-title":"B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma","volume":"133","author":"Wang","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1158\/1078-0432.CCR-11-0880","article-title":"Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness","volume":"18","author":"Lemke","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0025","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.21037\/jtd.2020.04.41","article-title":"Silencing of CD276 suppresses lung cancer progression by regulating integrin signaling","volume":"12","author":"Li","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0030","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/sj.bjc.6605375","article-title":"Clinical importance of B7-H3 expression in human pancreatic cancer","volume":"101","author":"Yamato","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0035","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/jcm7070172","article-title":"Tumor B7-H3 (CD276) expression and survival in pancreatic cancer","volume":"7","author":"Inamura","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0040","first-page":"7185","article-title":"Expression of CD24 and B7-H3 in breast cancer and the clinical significance","volume":"14","author":"Cong","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0045","doi-asserted-by":"crossref","first-page":"19458","DOI":"10.1073\/pnas.0709802104","article-title":"B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome","volume":"104","author":"Zang","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0050","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1158\/0008-5472.CAN-07-1068","article-title":"B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy","volume":"67","author":"Roth","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0055","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/modpathol.2010.95","article-title":"Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas","volume":"23","author":"Zang","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0060","first-page":"4048","article-title":"Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors","volume":"61","author":"Modak","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0065","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/ijc.27566","article-title":"B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer","volume":"131","author":"Ingebrigtsen","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0070","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.juro.2011.04.103","article-title":"B7-H3 over expression in prostate cancer promotes tumor cell progression","volume":"186","author":"Yuan","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0075","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s00262-012-1278-5","article-title":"B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence","volume":"61","author":"Sun","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0080","article-title":"B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis","volume":"8","author":"Wang","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0085","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3390\/jpm13020369","article-title":"The role of molecular imaging in personalized medicine","volume":"13","author":"Salih","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0090","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.7150\/thno.25575","article-title":"Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a","volume":"8","author":"Burvenich","year":"2018","journal-title":"Theranostics."},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nucmedbio.2017.12.004","article-title":"212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models","volume":"58","author":"Kasten","year":"2018","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0100","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1200\/JCO.20.01974","article-title":"B7H3-directed intraperitoneal radioimmunotherapy with radioiodinated ombur-tamab for desmoplastic small round cell tumor and other peritoneal tumors: results of a phase I study","volume":"38","author":"Modak","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0105","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-022-01383-4","article-title":"Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies","volume":"15","author":"Kramer","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ymeth.2013.09.015","article-title":"Engineered antibodies for molecular imaging of cancer","volume":"65","author":"Wu","year":"2014","journal-title":"Methods."},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.molimm.2015.04.001","article-title":"In vivo imaging with antibodies and engineered fragments","volume":"67","author":"Freise","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0120","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.18632\/oncotarget.13910","article-title":"Quantitative assessment of zirconium-89 labeled cetuximab using PET\/CT imaging in patients with advanced head and neck cancer: a theragnostic approach","volume":"8","author":"Even","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0125","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","article-title":"Affibody molecules in biotechnological and medical applications","volume":"35","author":"St\u00e5hl","year":"2017","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0130","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2967\/jnumed.117.199901","article-title":"Same-day imaging using small proteins: clinical experience and translational prospects in oncology","volume":"59","author":"Krasniqi","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0135","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3892\/ijo.2016.3721","article-title":"Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator","volume":"49","author":"Andersson","year":"2016","journal-title":"Int J Oncol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0140","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00726-018-2571-1","article-title":"Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules","volume":"50","author":"Oroujeni","year":"2018","journal-title":"Amino Acids"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0145","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/0008-5472.CAN-05-3521","article-title":"Tumor imaging using a picomolar affinity HER2 binding affibody molecule","volume":"66","author":"Orlova","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0150","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.3390\/ijms22052770","article-title":"Preclinical evaluation of 99mTc-ZHER2:41071, a second-generation Affibody-based HER2-visualizing imaging probe with a low renal uptake","volume":"22","author":"Oroujeni","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0155","doi-asserted-by":"crossref","first-page":"15226","DOI":"10.1038\/srep15226","article-title":"Affibody-mediated PET imaging of HER3 expression in malignant tumours","volume":"5","author":"Rosestedt","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0160","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1021\/mp500284t","article-title":"Gallium-68-labeled affibody molecule for PET imaging of PDGFRbeta expression in vivo","volume":"11","author":"Strand","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0165","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/pharmaceutics14071475","article-title":"Preclinical evaluation of a new format of 68Ga- and 111In-labeled Affibody molecule ZIGF-1R:4551 for the visualization of IGF-1R expression in malignant tumors using PET and SPECT","volume":"14","author":"Liu","year":"2022","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0170","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1021\/acs.molpharmaceut.6b00502","article-title":"Comparative evaluation of Affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX","volume":"13","author":"Garousi","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0175","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2967\/jnumed.113.131243","article-title":"First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 Affibody molecule","volume":"55","author":"S\u00f6rensen","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0180","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7150\/thno.13502","article-title":"Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET\/CT","volume":"6","author":"S\u00f6rensen","year":"2016","journal-title":"Theranostics."},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0185","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.122.265364","article-title":"HER2-targeting [68Ga]Ga-ABY-025 PET predicts early metabolic response in breast cancer patients - results from a Phase II study","author":"Alhuseinalkhudhur","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0190","first-page":"435","article-title":"Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labelled tracers","volume":"23","author":"W\u00e5llberg","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0195","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1007\/s00259-009-1176-z","article-title":"Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging","volume":"36","author":"Tran","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0200","first-page":"485","article-title":"Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies","volume":"58","author":"Adams","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0205","first-page":"4750","article-title":"High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules","volume":"61","author":"Adams","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0210","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1158\/1078-0432.CCR-05-2217","article-title":"Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers","volume":"12","author":"Adams","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0215","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2967\/jnumed.111.101527","article-title":"Tumor targeting using Affibody molecules: interplay of affinity, target expression level, and binding site composition","volume":"53","author":"Tolmachev","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0220","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jmb.2007.12.060","article-title":"Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule","volume":"376","author":"Friedman","year":"2008","journal-title":"J Mol Biol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/0d29f87c-8dfb-4694-abc7-7284a970910d","article-title":"Inhibiting HER3-mediated tumor cell growth with Affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification","volume":"8","author":"Malm","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0230","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jmb.2011.01.033","article-title":"Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor \u03b2 in vivo","volume":"407","author":"Lindborg","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0235","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3390\/pharmaceutics14091780","article-title":"Evaluation of an Affibody-based binder for imaging of immune check-point molecule B7-H3","volume":"14","author":"Oroujeni","year":"2022","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0240","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.nucmedbio.2010.02.009","article-title":"Kit formulation for 99mTc-labeling of recombinant anti-HER2 affibody molecules with a C-terminally engineered cysteine","volume":"37","author":"Ahlgren","year":"2010","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0245","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.apradiso.2006.03.002","article-title":"Automated, high-resolution cellular retention and uptake studies in vitro","volume":"64","author":"Bj\u00f6rke","year":"2006","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0250","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bbrc.2012.10.008","article-title":"Deciphering complex protein interaction kinetics using Interaction Map","volume":"428","author":"Altschuh","year":"2012","journal-title":"Biochem Biophys Commun"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0255","first-page":"274","article-title":"Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry","volume":"50","author":"Tolmachev","year":"2009","journal-title":"JNM."},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0260","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MNM.0b013e3282f3a515","article-title":"PET versus SPECT: strengths, limitations and challenges","volume":"29","author":"Rahmim","year":"2008","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0265","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.pcad.2015.02.002","article-title":"Advances in SPECT and PET hardware","volume":"57","author":"Slomka","year":"2015","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2004.09.001","article-title":"New directions in the coordination chemistry of 99mTc: a reflection on technetium core structures and a strategy for new chelate design","volume":"32","author":"Banerjee","year":"2005","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0275","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2967\/jnumed.108.056929","article-title":"Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine","volume":"50","author":"Ahlgren","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0280","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00726-011-0927-x","article-title":"Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant affibody molecules","volume":"42","author":"Altai","year":"2012","journal-title":"Amino Acids"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0285","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2967\/jnumed.110.083592","article-title":"Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties","volume":"52","author":"W\u00e5llberg","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0290","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1021\/jm400218y","article-title":"HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules","volume":"56","author":"Hofstr\u00f6m","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0295","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00726-014-1859-z","article-title":"Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression","volume":"47","author":"Mitran","year":"2015","journal-title":"Amino Acids"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0300","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ejmech.2014.09.082","article-title":"Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re","volume":"87","author":"Altai","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0305","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3390\/pharmaceutics14051092","article-title":"Experimental therapy of HER2-expressing xenografts using the second-generation HER2-targeting Affibody molecule 188Re-ZHER2:41071","volume":"14","author":"Liu","year":"2022","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0310","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/156800908785133141","article-title":"The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion","volume":"8","author":"Chen","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0315","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1021\/bc1002357","article-title":"HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [99mTc(CO)\u2083] (+) and shows improved biodistribution with reduced hepatic radioactivity accumulation","volume":"21","author":"Tolmachev","year":"2010","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2023.108384_bb0325","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3892\/or.2015.4046","article-title":"Comparative evaluation of 111In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors","volume":"34","author":"Andersson","year":"2015","journal-title":"Oncol Rep"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805123000720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805123000720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:31:43Z","timestamp":1760848303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805123000720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":64,"alternative-id":["S0969805123000720"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2023.108384","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2023.108384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108384"}}